icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Renewal of inclusion
Clinical Benefit
Substantial
The actual benefit of DOTAREM remains substantial.
Clinical Added Value
minor
DOTAREM offers a minor improvement in actual benefit (level IV) in terms of safety over gadolinium-based contrast media presenting a high (OMNISCAN, MAGNEVIST) or moderate (MULTIHANCE) risk of nephrogenic systemic fibrosis according to the European Medicines Agency classification.
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
DczkkxLwv14RaJzb